Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation.
Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC, widely recognized as one of the world’s leading conferences dedicated to artificial intelligence and accelerated computing. The event brought together more than 25,000 in-person attendees with a program that featured more than 1,000 sessions presented by technology leaders, researchers, developers and major global companies, including numerous Fortune 500 organizations.
GTC 2026 showcased the latest advances in artificial intelligence across multiple domains—from physical AI factories and agentic AI to advanced inference technologies—highlighting how these innovations are evolving rapidly. The event also featured major announcements, including the addition of millions of openly accessible protein complexes to the AlphaFold Database by the European Bioinformatics Institute, and the release of Proteina-Complexa, a fully atomistic generative model that can enhance the modeling of challenging targets such as GPCRs.
Biophytis’ presence at GTC was in collaboration with LynxKite Technologies and Nebius, combining Biophytis’ deep expertise in aging biology with LynxKite’s advanced artificial intelligence capabilities and Nebius full stack AI cloud. Together, LynxKite and Biophytis are developing AI-driven computational approaches designed to accelerate drug discovery in longevity, powered by Nebius AI Cloud.
This collaboration positions the partners at the forefront of innovation in the rapidly growing $1.5 trillion longevity market.
During the conference, Biophytis held meetings with investors and industrial partners to present its AI-driven drug discovery platform and explore potential collaborations in the field of longevity.
The Company also participated in a live demonstration at the Nebius booth, showcasing the MAS receptor and its lead drug candidate BIO101, illustrating how advanced computational tools and large-scale GPU computing can support the modeling of biological targets and accelerate the discovery of new therapeutic candidates targeting age-related diseases.
“Being invited to participate in NVIDIA GTC highlights the importance of the work we are conducting at the intersection of artificial intelligence and aging biology,” said Stanislas Veillet, PhD, Chairman and CEO of Biophytis. “Our collaboration with LynxKite reflects our ambition to leverage advanced computational technologies to accelerate innovation in the field of longevity and muscle health.”
